Dexmedetomidine Hydrochloride Group

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Delirium

Conditions

Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders, Mental Disorders, Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Signs and Symptoms, Dexmedetomidine, Hypnotics and Sedatives, Central Nervous System Depressants, Physiological Effects of Drugs, Analgesics, Non-Narcotic, Analgesics, Molecular Mechanisms of Pharmacological Action

Trial Timeline

Dec 1, 2019 → Mar 1, 2029

NCT ID

NCT04289142

About Dexmedetomidine Hydrochloride Group

Dexmedetomidine Hydrochloride Group is a approved stage product being developed by Brain Biotech for Delirium. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04289142. Target conditions include Delirium, Cognitive Dysfunction, Cognition Disorder.

What happened to similar drugs?

4 of 12 similar drugs in Delirium were approved

Approved (4) Terminated (3) Active (6)

🔄Suvorexant + PlaceboMerckPhase 3

✅Rivastigmine + PlaceboNovartisApproved

🔄Rivastigmine prevention of deliriumNovartisPhase 3

🔄Rivastigmine transdermal patch + placebo patchNovartisPhase 3

✅Rivastigmine PatchNovartisApproved

❌Dexmedetomidine + PlaceboPfizerPhase 3

✅ParecoxibPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04289142	Approved	Recruiting	Dec 1, 2019	Mar 1, 2029	Delirium

Competing Products

17 competing products in Delirium

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Suvorexant + Placebo	Merck	Phase 3	40
Suvorexant 20 mg + Placebo	Merck	Phase 2	35
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Rivastigmine Patch	Novartis	Approved	43
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17